Working in the regulatory system for medicines authorisation

28 May 2025 - Utrecht

In this interactive workshop, we will tell you all about the CBG-MEB and the important work that we do, making sure that patients can rely on safe and effective medicines. You will hear about the different roles, and how these roles contribute to the process of assessing the dossier of a medicine. We will give you a glimpse of how a benefit/risk assessment is made and why this can be a challenging and complicated process!

About CBG | MEB

Every year, more than 11 million people in the Netherlands use medications prescribed by a doctor. And this number increases even further if you include over-the counter medicines. Our organization, the Medicines Evaluation Board is responsible for approving drugs for the Dutch market and has an important advisory role within the EMA when it comes to products for the European market. The Board consists of 17 experts who, in addition to their work for the MEB, often hold positions in which they treat patients in practice. College decisions are prepared by our 500 MEB employees who are involved in decision-making on a daily basis.

Dr. Emmely de Vries | Senior Clinical Assessor | CBG | MEB

Emmely de Vries studied Biomedical Sciences at Utrecht University, followed by a master in Neuroscience and Cognition. She wrote her PhD thesis on the effect of inflammation and fasting on thyroid hormone metabolism at the University of Amsterdam. After a 3 year postdoc on the effects of food intake on the metabolism of medicines, she left academia to pursue a career which was more placed on the interface of science and society. Emmely has worked with the CBG-MEB as a clinical assessor since 2018, specialized in the assessment of rare metabolic disorders and endocrinology. Since the end of 2023 she is the Dutch member of the Committee for Advanced Therapies and as such contributes to the approval process of advanced therapeutics in the EU.

FULL PROGRAMME HERE